References
- Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al.; International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49. doi:https://doi.org/10.1016/s0022-5223(97)70397-0.
- Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076. doi:https://doi.org/10.1001/jama.2010.261.
- Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013; 8(8):1050–1058. doi:https://doi.org/10.1097/JTO.0b013e318293dc45.
- Borm KJ, Oechsner M, Schiller K, Peeken JC, Dapper H, Münch S, et al. Prognostic factors in stereotactic body radiotherapy of lung metastases. Strahlenther Onkol. 2018;194(10):886–893. doi:https://doi.org/10.1007/s00066-018-1335-x.
- Filippi AR, Guerrera F, Badellino S, Ceccarelli M, Castiglione A, Guarneri A, et al. Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer. Clin Oncol (R Coll Radiol). 2016;28(8):505–512. doi:https://doi.org/10.1016/j.clon.2016.02.001.
- Lodeweges JE, Klinkenberg TJ, Ubbels JF, Groen HJM, Langendijk JA, Widder J, et al. Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases. J Thorac Oncol. 2017;12(9):1442–5. doi:https://doi.org/10.1016/j.jtho.2017.05.015.
- Sharma A, Duijm M, Oomen-de Hoop E, Aerts JG, Verhoef C, Hoogeman M, et al. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncologica (Stockholm, Sweden). 2018;57(8):1031–1037. doi:https://doi.org/10.1080/0284186X.2018.1445285.
- Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". Lung Cancer. 2016;97:51–8. doi:https://doi.org/10.1016/j.lungcan.2016.04.012.
- Helou J, Thibault I, Poon I, Chiang A, Jain S, Soliman H, et al. Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter. Int J Radiat Oncol Biol Phys. 2017;98(2):419–427. doi:https://doi.org/10.1016/j.ijrobp.2017.02.093.
- Bae SH, Kim MS, Cho CK, Kang J-K, Kang HJ, Kim YH, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012;106(2):138–143. doi:https://doi.org/10.1002/jso.23058.
- Loi M, Franceschini D, Dominici L, Franzese C, Chiola I, Comito T, et al. Stereotactic radiotherapy for ultra-central lung oligometastases in non-small-cell lung cancer. Cancers. 2020;12(4):885. doi:https://doi.org/10.3390/cancers12040885.
- Cooke R, Camilleri P, Chu K-Y, O'Cathail SM, Robinson M, Van Den Heuvel F, et al. Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. Tech Innov Patient Support Radiat Oncol. 2020;13:24–30. doi:https://doi.org/10.1016/j.tipsro.2020.01.002.
- Chen H, Laba JM, Zayed S, Boldt RG, Palma DA, Louie AV, et al. Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review. J Thorac Oncol. 2019;14(8):1332–1342. doi:https://doi.org/10.1016/j.jtho.2019.04.018.
- Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glick D, et al. SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial. Clin Lung Cancer. 2018;19(4):e529–e532. doi:https://doi.org/10.1016/j.cllc.2018.04.001.
- Ogawa Y, Shibamoto Y, Hashizume C, Kondo T, Iwata H, Tomita N, et al. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT. Radiat Oncol. 2018;13(1):136. doi:https://doi.org/10.1186/s13014-018-1080-4.
- Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol. 2012;7(9):1462–1465. doi:https://doi.org/10.1097/JTO.0b013e31825f22ce.
- Antonoff MB, Correa AM, Sepesi B, Nguyen QN, Walsh GL, Swisher SG, et al. Salvage pulmonary resection after stereotactic body radiotherapy: a feasible and safe option for local failure in selected patients. J Thorac Cardiovasc Surg. 2017;154(2):689–699. doi:https://doi.org/10.1016/j.jtcvs.2017.03.142.
- Hamaji M, Mitsuyoshi T, Yoshizawa A, Sato T, Matsuo Y, Chen-Yoshikawa TF, et al. Salvage pulmonary metastasectomy for local relapse after stereotactic body radiotherapy. Ann Thorac Surg. 2018;105(4):e165–e168. doi:https://doi.org/10.1016/j.athoracsur.2017.11.003.
- Hamakawa H, Takahashi Y, Sakanoue I, Saito T, Date N, Tomii K, et al. Salvage pulmonary operations following stereotactic body radiotherapy for small primary and metastatic lung tumors: evaluation of the operative procedures. Technol Cancer Res Treat. 2018;7:1533033818807431. doi:https://doi.org/10.1177/1533033818807431.
- Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123(2):227–233. doi:https://doi.org/10.1016/j.radonc.2017.01.013.
- Morita M, Sasaki Y, Saijo N. The antitumor activity of radiation therapy is reduced in patients with non-small-cell carcinoma of the lung refractory to chemotherapy. Ann Oncol. 1992; 3(4):273–6. doi:https://doi.org/10.1093/oxfordjournals.annonc.a058177.
- Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 2013;19(3):200–207. doi:https://doi.org/10.1097/PPO.0b013e318292e4e3.
- Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, et al. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg. 2005;79(1):278–282; discussion 283. doi:https://doi.org/10.1016/j.athoracsur.2004.06.096.
- Masai K, Sakurai H, Sukeda A, Suzuki S, Asakura K, Nakagawa K, et al. Prognostic impact of margin distance and tumor spread through air spaces in limited resection for primary lung cancer. J Thoracic Oncol. 2017;12(12):1788–1797. doi:https://doi.org/10.1016/j.jtho.2017.08.015.
- Shiono S, Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, et al. Outcomes of segmentectomy and wedge resection for pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg. 2017;51(3):504–510.
- Higashiyama M, Tokunaga T, Nakagiri T, Ishida D, Kuno H, Okami J, et al. Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection. Gen Thorac Cardiovasc Surg. 2015;63(6):320–330. doi:https://doi.org/10.1007/s11748-015-0544-9.
- Hisao A, Keiju A, Masaya Y. Wedge resection versus anatomic resection: extent of surgical resection for stage I and II lung cancer. Am Soc Clin Oncol Educ Book. 2017; 37:426–433. doi:https://doi.org/10.1200/EDBK_179730.
- Davini F, Ricciardi S, Zirafa CC, Romano G, Alì G, Fontanini G, et al. Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. Int J Colorectal Dis. 2020;35(1):9–18. doi:https://doi.org/10.1007/s00384-019-03386-z.
- Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, et al. Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019;157(4):1648–1655. doi:https://doi.org/10.1016/j.jtcvs.2018.10.156.
- Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol. 2006; 13(11):1538–1544. doi:https://doi.org/10.1245/s10434-006-9100-2.
- Chung JH, Lee SH, Yi E, Lim JY, Jung JS, Son HS, et al. Impact of resection margin length and tumor depth on the local recurrence after thoracoscopic pulmonary wedge resection of a single colorectal metastasis. J Thorac Dis. 2019;1(5):1879–87. doi:https://doi.org/10.21037/jtd.2019.05.12.
- Wang Z, Kong Q-T, Li J, Wu X-H, Li B, Shen Z-T, et al. Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. J Thorac Dis. 2015; 7(3):407–12.
- Berkovic P, Gulyban A, Defraene G, Swenen L, Dechambre D, Nguyen PV, et al. Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases. BMC Cancer. 2020;20(1):402. doi:https://doi.org/10.1186/s12885-020-06906-1.
- Kobayashi N, Kobayashi K, Kikuchi S, Goto Y, Ichimura H, Endo K, et al. Long-term pulmonary function after surgery for lung cancer. Interact Cardiovasc Thorac Surg. 2017;24(5):727–732. doi:https://doi.org/10.1093/icvts/ivw414.
- Brunelli A, Xiumé F, Refai M, Salati M, Marasco R, Sciarra V, et al. Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. Chest. 2007;131(1):141–147. doi:https://doi.org/10.1378/chest.06-1345.
- Bishawi M, Kim B, Moore WH, Bilfinger TV. Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys. 2012; 82(1):e107-10–e110. doi:https://doi.org/10.1016/j.ijrobp.2011.01.037.
- Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88(5):1092–1099. doi:https://doi.org/10.1016/j.ijrobp.2013.12.050.
- Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol. 2009; 4(7):838–844. doi:https://doi.org/10.1097/JTO.0b013e3181a99ff6.
- Prezzano KM, Ma SJ, Hermann GM, Rivers CI, Gomez-Suescun JA, Singh AK, et al. Stereotactic body radiation therapy for non-small cell lung cancer: a review. World J Clin Oncol. 2019;10(1):14–27. doi:https://doi.org/10.5306/wjco.v10.i1.14.
- Bongers EM, Botticella A, Palma DA, Haasbeek CJA, Warner A, Verbakel WFAR, et al. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. RadiotherOncol. 2013; 109(1):95–9. doi:https://doi.org/10.1016/j.radonc.2013.10.011.
- Baker R, Han G, Sarangkasiri S, DeMarco MLou, Turke C, Stevens CW, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2013; 85(1):190–195. doi:https://doi.org/10.1016/j.ijrobp.2012.03.041.
- Chapman CH, McGuinness C, Gottschalk AR, Yom SS, Garsa AA, Anwar M, et al. Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy. J Appl Clin Med Phys. 2018;19(4):48–57. doi:https://doi.org/10.1002/acm2.12338.